cisplatin, docetaxel

Phase 3Small molecule

cisplatin, docetaxel is one of 85 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Lung CarcinomaActive, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Small Cell Lung CancerPhase 3

Active, not recruiting

Lung CarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

cisplatin, docetaxel

NNational Guard Health Affairs

Phase 3

3 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Vizimpro

Pfizer

Preclinical

4 5

Ofev

Boehringer Ingelheim

Preclinical

7 6

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Treatment

1 9

Vidaza

Bristol-Myers Squibb

Preclinical

1 10

Huaier Granule

QQidong Gaitianli Medicines Co., Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer

Suspended·NNational Guard Health Affairs·Phase 2·NCT01356303·50 enrolled

Customizing First Line Chemotherapy in Advanced Non-Small Cell Lung Cancer

Terminated·NNational Guard Health Affairs·Phase 2·NCT01356368·3 enrolled

Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer

Completed·EEuropean Lung Cancer Working Party·Phase 3·NCT00622349·707 enrolled

Lung Carcinoma1 trial

Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma

Terminated·SSpanish Lung Cancer Group·Phase 3·NCT00617656·382 enrolled

Small Cell Lung Cancer1 trial

Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES)

Completed·UUniversity Hospital, Antwerp·Phase 3·NCT00771563·104 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for cisplatin, docetaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cisplatin, docetaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cisplatin, docetaxel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Guard Health Affairs company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNational Guard Health Affairs

cisplatin, docetaxel

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

Lung Carcinoma1 trial

Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News